Anti-inflammatory effects of ADAMTS-4 in a mouse model of ischemic stroke

GLIA

Volumn 64, Issue 9, 2016, Pages 1492-1507

  Lemarchant, Sighild ^a   Dunghana, Hiramani ^a   Pomeshchik, Yuriy ^a   Leinonen, Henri ^a   Kolosowska, Natalia ^a   Korhonen, Paula ^a   Kanninen, Katja M ^a   García Berrocoso, Teresa ^b   Montaner, Joan ^b   Malm, Tarja ^a   Koistinaho, Jari ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

ADAMTS 4; astrocyte; microglia; neuroinflammation; stroke

Indexed keywords

AGGRECANASE 1; ANTIINFLAMMATORY AGENT; ARGINASE 1; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; RECOMBINANT A DISINTEGRIN AND METALLOPROTEINASE WITH THROMBOSPONDIN MOTIFS 4; RECOMBINANT ENZYME; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE CULTURE; ASTROCYTOSIS; BRAIN ISCHEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; FEASIBILITY STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION; MALE; MICROGLIAL CELL CULTURE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; MOUSE MODEL; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84979085370     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.23017     Document Type: Article

References (61)

1. Amantea D, Micieli G, Tassorelli C, Cuartero MI, Ballesteros I, Certo M, Moro MA, Lizasoain I, Bagetta G. 2015. Rational modulation of the innate immune system for neuroprotection in ischemic stroke. Front Neurosci 9:147-
2. Ashlin TG, Kwan AP, Ramji DP. 2013. Regulation of ADAMTS-1, −4 and −5 expression in human macrophages: Differential regulation by key cytokines implicated in atherosclerosis and novel synergism between TL1A and IL-17. Cytokine 64:234−242.
3. Bartus K, James ND, Didangelos A, Bosch KD, Verhaagen J, Yáñez-Muñoz RJ, Rogers JH, Schneider BL, Muir EM, Bradbury EJ. 2014. Large-scale chondroitin sulfate proteoglycan digestion with chondroitinase gene therapy leads to reduced pathology and modulates macrophage phenotype following spinal cord contusion injury. J Neurosci 34:4822–4836.
4. Bradbury EJ, Carter LM. 2011. Manipulating the glial scar: Chondroitinase ABC as a therapy for spinal cord injury. Brain Res Bull 84:306–316.
5. Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon SB. 2002. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 416:636–640.
6. Cai P, Luo H, Xu H, Zhu X, Xu W, Dai Y, Xiao J, Cao Y, Zhao Y, Zhao BQ, Fan W. 2015. Recombinant ADAMTS 13 Attenuates Brain Injury After Intracerebral Hemorrhage. Stroke 46:2647–2653.
7. Cassé F, Bardou I, Danglot L, Briens A, Montagne A, Parcq J, Alahari A, Galli T, Vivien D, Docagne F. 2012. Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. J Neurosci 32:5186–5199.
8. Chhor V, Le Charpentier T, Lebon S, Oré MV, Celador IL, Josserand J, Degos V, Jacotot E, Hagberg H, Sävman K, Mallard C, Gressens P, Fleiss B. 2013. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun 32:70–85.
9. Cross AK, Haddock G, Stock CJ, Allan S, Surr J, Bunning RA, Buttle DJ, Woodroofe MN. 2006. ADAMTS-1 and −4 are up-regulated following transient middle cerebral artery occlusion in the rat and their expression is modulated by TNF in cultured astrocytes. Brain Res 1088:19–30.
10. Demircan K, Yonezawa T, Takigawa T, Topcu V, Erdogan S, Ucar F, Armutcu F, Yigitoglu MR, Ninomiya Y, Hirohata S. 2013. ADAMTS1, ADAMTS5, ADAMTS9 and aggrecanase-generated proteoglycan fragments are induced following spinal cord injury in mouse. Neurosci Lett 544:25–30.
11. Denorme F, Langhauser F, Desender L, Vandenbulcke A, Rottensteiner H, Plaimauer B, François O, Andersson T, Deckmyn H, Scheiflinger F, Kleinschnitz C, Vanhoorelbeke K, De Meyer SF. 2016. ADAMTS13-mediated thrombolysis of t-PA resistant occlusions in ischemic stroke in mice. Blood 127:2337–2345.
12. Didangelos A, Iberl M, Vinsland E, Bartus K, Bradbury EJ. 2014. Regulation of IL-10 by chondroitinase ABC promotes a distinct immune response following spinal cord injury. J Neurosci 34:16424–16432.
13. Franco R, Fernández-Suárez D. 2015. Alternatively activated microglia and macrophages in the central nervous system. Prog Neurobiol 131:65–86.
14. Gensel JC, Zhang B. 2015. Macrophage activation and its role in repair and pathology after spinal cord injury. Brain Res 1619:1–11.
15. Gherardini L, Gennaro M, Pizzorusso T. 2015. Perilesional treatment with chondroitinase ABC and motor training promote functional recovery after stroke in rats. Cereb Cortex 25:202–212.
16. Goldring MB, Otero M. 2011. Inflammation in osteoarthritis. Curr Opin Rheumatol 23:471−478.
17. Haddock G, Cross AK, Plumb J, Surr J, Buttle DJ, Bunning RA, Woodroofe MN. 2006. Expression of ADAMTS-1, -4, -5 and TIMP-3 in normal and multiple sclerosis CNS white matter. Mult Scler 12:386–396.
18. Hamel MG, Ajmo JM, Leonardo CC, Zuo F, Sandy JD, Gottschall PE. 2008. Multimodal signaling by the ADAMTSs (a disintegrin and metalloproteinase with thrombospondin motifs) promotes neurite extension. Exp Neurol 210:428–440.
19. Hamel MG, Mayer J, Gottschall PE. 2005. Altered production and proteolytic processing of brevican by transforming growth factor beta in cultured astrocytes. J Neurochem 93:1533–1541.
20. Hellewell S, Semple BD, Morganti-Kossmann MC. 2016. Therapies negating neuroinflammation after brain trauma. Brain Res 1640:36–56.
21. Hill JJ, Jin K, Mao XO, Xie L, Greenberg DA. 2012. Intracerebral chondroitinase ABC and heparan sulfate proteoglycan glypican improve outcome from chronic stroke in rats. Proc Natl Acad Sci U S A 109:9155–9160.
22. Hobohm C, Günther A, Grosche J, Rossner S, Schneider D, Brückner G. 2005. Decomposition and long-lasting downregulation of extracellular matrix in perineuronal nets induced by focal cerebral ischemia in rats. J Neurosci Res 80:539–548.
23. Howell MD, Torres-Collado AX, Iruela-Arispe ML, Gottschall PE. 2012. Selective decline of synaptic protein levels in the frontal cortex of female mice deficient in the extracellular metalloproteinase ADAMTS1. PLoS One 7:e47226-
24. Hsu YP, Staton CA, Cross N, Buttle DJ. 2012. Anti-angiogenic properties of ADAMTS-4 in vitro. Int J Exp Pathol 93:70–77.
25. Huh JE, Seo BK, Park YC, Kim JI, Lee JD, Choi DY, Baek YH, Park DS. 2012. WIN-34B, a new herbal medicine, inhibits the inflammatory response by inactivating IκB-α phosphorylation and mitogen activated protein kinase pathways in fibroblast-like synoviocytes. J Ethnopharmacol 143:779–786.
26. Jha MK, Lee WH, Suk K. 2016. Functional polarization of neuroglia: Implications in neuroinflammation and neurological disorders. Biochem Pharmacol103 1–16.
27. Koh TJ, Novak ML, Mirza RE. 2013. Assessing macrophage phenotype during tissue repair. –Methods Mol Biol 1037:507–518.
28. Korhonen P, Kanninen KM, Lehtonen Š, Lemarchant S, Puttonen KA, Oksanen M, Dhungana H, Loppi S, Pollari E, Wojciechowski S, Kidin I, García-Berrocoso T, Giralt D, Montaner J, Koistinaho J, Malm T. 2015. Immunomodulation by interleukin-33 is protective in stroke through modulation of inflammation. Brain Behav Immun 49:322–336.
29. Krstic D, Rodriguez M, Knuesel I. 2012. Regulated proteolytic processing of Reelin through interplay of tissue plasminogen activator (tPA), ADAMTS-4, ADAMTS-5, and their modulators. PLoS One 7:e47793-
30. Lemarchant S, Pomeshchik Y, Kidin I, Kärkkäinen V, Valonen P, Lehtonen S, Goldsteins G, Malm T, Kanninen K, Koistinaho J. 2016. ADAMTS-4 promotes neurodegeneration in a mouse model of amyotrophic lateral sclerosis. Mol Neurodegener 11:10-
31. Lemarchant S, Pruvost M, Hébert M, Gauberti M, Hommet Y, Briens A, Maubert E, Gueye Y, Féron F, Petite D, Mersel M, do Rego JC, Vaudry H, Koistinaho J, Ali C, Agin V, Emery E, Vivien D. 2014. tPA promotes ADAMTS-4-induced CSPG degradation, thereby enhancing neuroplasticity following spinal cord injury. Neurobiol Dis 66:28–42.
32. Lemarchant S, Pruvost M, Montaner J, Emery E, Vivien D, Kanninen K, Koistinaho J. 2013. ADAMTS proteoglycanases in the physiological and pathological central nervous system. J Neuroinflammation 10:133-
33. Malm T, Mariani M, Donovan LJ, Neilson L, Landreth GE. 2015. Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation. J Neuroinflammation 12:7
34. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677–686.
35. Marzolo MP, von Bernhardi R, Bu G, Inestrosa NC. 2000. Expression of alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP) in rat microglial cells. J Neurosci Res 60:401–411.
36. Mimata Y, Kamataki A, Oikawa S, Murakami K, Uzuki M, Shimamura T, Sawai T. 2012. Interleukin-6 upregulates expression of ADAMTS-4 in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Int J Rheum Dis 15:36–44.
37. Murray KN, Parry-Jones AR, Allan SM. 2015. Interleukin-1 and acute brain injury. Front Cell Neurosci 9:18-
38. Novak ML, Koh TJ. 2013. Phenotypic transitions of macrophages orchestrate tissue repair. Am J Pathol 183:1352–1363.
39. Pihlaja R, Koistinaho J, Kauppinen R, Sandholm J, Tanila H, Koistinaho M. 2011. Multiple cellular and molecular mechanisms are involved in human Aβ clearance by transplanted adult astrocytes. Glia 59:1643–1657.
40. Pocivavsek A, Burns MP, Rebeck GW. 2009. Low-density lipoprotein receptors regulate microglial inflammation through c-Jun N-terminal kinase. Glia 57:444–453.
41. Reid MJ, Cross AK, Haddock G, Allan SM, Stock CJ, Woodroofe MN, Buttle DJ, Bunning RA. 2009. ADAMTS-9 expression is up-regulated following transient middle cerebral artery occlusion (tMCAo) in the rat. Neurosci Lett 452:252–257.
42. Ren P, Zhang L, Xu G, Palmero LC, Albini PT, Coselli JS, Shen YH, LeMaire SA. 2013. ADAMTS-1 and ADAMTS-4 levels are elevated in thoracic aortic aneurysms and dissections. Ann Thorac Surg 95:570–577.
43. Rolova T, Puli L, Magga J, Dhungana H, Kanninen K, Wojciehowski S, Salminen A, Tanila H, Koistinaho J, Malm T. 2014. Complex regulation of acute and chronic neuroinflammatory responses in mouse models deficient for nuclear factor kappa B p50 subunit. Neurobiol Dis 64:16–29.
44. Sasaki M, Seo-Kiryu S, Kato R, Kita S, Kiyama H. 2001. A disintegrin and metalloprotease with thrombospondin type1 motifs (ADAMTS-1) and IL-1 receptor type 1 mRNAs are simultaneously induced in nerve injured motor neurons. Brain Res Mol Brain Res 89:158–163.
45. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. 2011. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta1813 878–888.
46. Shuaib A, Xu Wang C, Yang T, Noor R. 2002. Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Stroke 33:3033–3037.
47. Skaper SD, Facci L, Giusti P. 2014. Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: A review. CNS Neurol Disord Drug Targets 13:1654–1666.
48. Soleman S, Yip PK, Duricki DA, Moon LD. 2012. Delayed treatment with chondroitinase ABC promotes sensorimotor recovery and plasticity after stroke in aged rats. Brain 135:1210–1223.
49. Séguin CA, Bojarski M, Pilliar RM, Roughley PJ, Kandel RA. 2006. Differential regulation of matrix degrading enzymes in a TNFalpha-induced model of nucleus pulposus tissue degeneration. Matrix Biol 25:409–418.
50. Tauchi R, Imagama S, Natori T, Ohgomori T, Muramoto A, Shinjo R, Matsuyama Y, Ishiguro N, Kadomatsu K. 2012. The endogenous proteoglycan-degrading enzyme ADAMTS-4 promotes functional recovery after spinal cord injury. J Neuroinflammation 9:53-
51. Tauchi R, Imagama S, Ohgomori T, Natori T, Shinjo R, Ishiguro N, Kadomatsu K. 2012. ADAMTS-13 is produced by glial cells and upregulated after spinal cord injury. Neurosci Lett 517:1–6.
52. Tian Y, Yuan W, Fujita N, Wang J, Wang H, Shapiro IM, Risbud MV. 2013. Inflammatory cytokines associated with degenerative disc disease control aggrecanase-1 (ADAMTS-4) expression in nucleus pulposus cells through MAPK and NF-κB. Am J Pathol 182:2310–2321.
53. Wang L, Fan W, Cai P, Fan M, Zhu X, Dai Y, Sun C, Cheng Y, Zheng P, Zhao BQ. 2013. Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice. Ann Neurol 73:189–198.
54. Wågsäter D, Björk H, Zhu C, Björkegren J, Valen G, Hamsten A, Eriksson P. 2008. ADAMTS-4 and −8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. Atherosclerosis 196:514–522.
55. Yamamoto K, Owen K, Parker AE, Scilabra SD, Dudhia J, Strickland DK, Troeberg L, Nagase H. 2014. Low density lipoprotein receptor-related protein 1 (LRP1)-mediated endocytic clearance of a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4): Functional differences of non-catalytic domains of ADAMTS-4 and ADAMTS-5 in LRP1 binding. J Biol Chem 289:6462–6474.
56. Yuan W, Matthews RT, Sandy JT, Gottschall PE. 2002. Association between protease-specific proteolytic cleavage of brevican and synaptic loss in the dentate gyrus of kainate-treated rats. Neuroscience 114:1091–1101.
57. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA. 2012. Genomic analysis of reactive astrogliosis. J Neurosci 32:6391–6410.
58. Zhang C, An J, Strickland DK, Yepes M. 2009. The low-density lipoprotein receptor-related protein 1 mediates tissue-type plasminogen activator-induced microglial activation in the ischemic brain. Am J Pathol 174:586–594.
59. Zhao BQ, Chauhan AK, Canault M, Patten IS, Yang JJ, Dockal M, Scheiflinger F, Wagner DD. 2009. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 114:3329–3334.
60. Zuo J, Neubauer D, Dyess K, Ferguson TA, Muir D. 1998. Degradation of chondroitin sulfate proteoglycan enhances the neurite-promoting potential of spinal cord tissue. Exp Neurol 154:654–662.
61. Zuo J, Neubauer D, Graham J, Krekoski CA, Ferguson TA, Muir D. 2002. Regeneration of axons after nerve transection repair is enhanced by degradation of chondroitin sulfate proteoglycan. Exp Neurol 176:221–228.